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Abstract: The nontherapeutic use of prescription medicines by individuals involved in sport 
is increasing. Anabolic-androgenic steroids (AAS) are the most widely abused drug. Much of 
our knowledge of the psychological and physiological effects of human growth hormone (hGH) 
and insulin has been learned from deﬁ  ciency states. As a consequence of the Internet revolution, 
previously unobtainable and expensive designer drugs, particularly recombinant human growth 
hormone (rhGH) and insulin, have become freely available at ridiculously discounted prices 
from countries such as China and are being abused. These drugs have various physiological and 
psychological effects and medical personnel must become aware that such prescription medicine 
abuse appears to be used not only for performance and cosmetic reasons, but as a consequence 
of psychological pre-morbidity.
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Introduction
Athletes, bodybuilders, and recreational weightlifters have been abusing anabolic-
androgenic steroids (AAS) since their synthetic production (Ruckzika et al 1935). 
They are a powerful group of synthetic compounds similar in chemical structure to 
the natural male steroid hormone testosterone (T) and dihydrotestosterone (DHT) 
(Haupt and Rovere 1984; Shahidi 2001). They differ from T by the addition of an 
ethyl, methyl, hydroxyl, or benzyl groups at one or more sites along the synthetic 
steroid structure (Figure 1).
The risks from chronic administration of AAS may appear relatively low when 
compared with the use of socially acceptable drugs such as tobacco and alcohol. 
The literature tends to rely heavily on speciﬁ  c case reports, identifying psychiatric 
or psychological disorder, because of the private and personal nature of the abuse of 
this class of drug (Pagonis et al 2006a; Papazisis et al 2007). AAS are taken for their 
desirable cosmetic effects, to increase size and in the belief that they enhance sport-
ing performance. AAS self-administration has increased over the last decade, in the 
wake of the demonstration that AAS increase muscle mass and strength in healthy 
adult males, over and above resistance training (Bhasin et al 1996). The administration 
of AAS has undesirable effects, which have been extensively reviewed (Haupt and 
Rovere 1984; Hartgens and Kuipers 2004; Hartgens et al 2004).
However, there may be other reasons why individuals abuse anabolic substances. 
Thirteen percent of 75 female weightlifters, who admitted to abusing AAS to gain 
muscle mass, had increased their weightlifting activities to be better able to defend 
themselves against men and also reported that they were previously sexually abused 
(Gruber and Pope 1999). It is believed that compulsive weightlifting and AAS 
abuse may represent a form of response to the trauma of sexual assault and also 
may assist in raising self-esteem. The psychiatric evaluation of dedicated female 
athletes also demonstrated the exhibition of ergogenic polysubstance dependence, Therapeutics and Clinical Risk Management 2008:4(3) 588
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often with significant co-morbidity (Gruber and Pope 
2000). Fifty six percent demonstrated hypomania during 
the “administration-phase” and 40% reported depressive 
symptoms during withdrawal. These athletes also displayed 
several psychiatric syndromes, previously ill-deﬁ  ned, such 
as obsessive compulsive disorder (OCD), rigid dietary 
practice, nontraditional gender roles, and chronic dissat-
isfaction and preoccupation with their physiques (muscle 
dysmorphia).
Pagonis and colleagues (2006b) has shown in a study 
of 160 AAS-abusing athletes compared with 160 placebo 
and controls that the wide range of psychiatric side effects 
induced by the abuse of AAS is correlated to the severity 
of abuse. The force of these side effects intensiﬁ  es as the 
abuse escalates.
The latest substances being abused by individuals, associ-
ated with sport, include recombinant human growth hormone 
(rhGH) or rhGH in combination with insulin (Sonksen 2001; 
Rennie 2003). Both are being used as ergogenic aids and as 
doping agents. They are currently taken in the belief that 
they increase skeletal muscle mass and improve performance 
(Jenkins 2001).
In Gruber and Pope’s study (1999), 14% of surveyed 
subjects also abused insulin and AAS. Insulin has a shorter 
history as a ‘doping agent’ when compared with both GH and 
AAS (Sonksen 2001). The use of AAS, rhGH, and insulin 
in the UK in bodybuilding and other sports has increased 
(Baker et al 2006) compared with a survey in 2001 (Grace 
et al 2001). AAS use has increased by 17%, insulin by 6%, 
and rhGH by 18%. Unless caught by urinalysis in the act, 
convicting a competitive sporting individual who has taken 
rhGH (Powrie et al 2007) and insulin (Coghlan 2001) is not 
possible. Insulin in acute abuse is inﬁ  nitely more danger-
ous than rhGH. The few cases that have been published 
are case histories of individuals who have been admitted 
to hospital following accidental insulin overdose (Konrad 
et al 1998; Rich et al 1998; Evans and Lynch 2003). They 
have a distorted body image and reported the condition of 
“reverse anorexia”, where they believed they were small and 
weak, despite being large and muscular (Pope et al 1993). 
The reasons for use of these anabolic agents appear to be 
based not only on peer review, but also scientiﬁ  c research 
(Sonksen 2001). Low self-esteem and unrealistic, muscular 
male body ideals, puts individuals at risk for negative body 
images and unhealthy eating and exercise habits. These 
individuals resort to drug-taking to counteract their altered 
body images. The legislation in the UK would appear to be 
permissive in allowing the bodybuilding fraternity no prob-
lems in obtaining their insulin supplies (Elkin et al 1997). 
Dawson (2001) identiﬁ  ed that 10% of 450 patients attending 
a needle exchange programme self-prescribed insulin for 
nontherapeutic purposes.
Physiological and biochemical 
aspects of growth hormone
The ability of the somatotroph cells in the anterior pituitary 
to synthesize and secrete the polypeptide, hGH, is determined 
by a gene called the Prophet of Pit-1 (PROP1). When hGH 
is translated, 70%–80% is secreted as a 191-amino-acid, 
4-helix bundle protein, and 20%–30% as a less abundant 
176-amino-acid form (Baumann 1991; Wu et al 1999) 
(Figure 2). Hypothalamic-releasing and hypothalamic-
inhibiting hormones acting via the hypophysial portal system 
control the secretion of hGH, which is secreted into the 
circulation (Melmed 2006).
In healthy persons, the hGH level is usually 0.2 µg.L−1 
throughout most of the day. There are approximately 10–12 
intermittent secretory bursts in a 24 hour period, mostly 
at night, when the level can rise to as much as 30 µg.L−1 
(Melmed 2006). HGH secretion declines at 14% per decade 
from the age of 20 years (Iranmanesh et al 1991).
HGH action is mediated by an hGH receptor, which is 
expressed mainly in the liver and is composed of dimers 
that change conformation when occupied by an hGH ligand 
(Brown et al 2005).
Cleavage of the hGH receptor provides a circulating hGH 
binding protein (GHBP), prolonging the half-life and mediat-
ing the transport of hGH (Argetsinger et al 1993).
Intracellular hGH signalling is decreased by suppres-
sors of cytokine signaling. HGH induces the synthesis of 
peripheral insulin-like growth factor I (IGF-I) (Le Roith 
et al 2001) while endocrine, autocrine, and paracrine IGF-I 
Figure 1 Testosterone is a steroid hormone from the androgen group. It is the principal 
male sex hormone and the “original” anabolic steroid.Therapeutics and Clinical Risk Management 2008:4(3) 589
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induces cell proliferation and is thought to inhibit apoptosis 
(O’Reilly et al 2006).
IGF-binding proteins (IGFBP) and their proteases 
regulate the access of ligands to the IGF-I receptor affecting 
its action. Levels of IGF-I are at their peak during late ado-
lescence and decline throughout adulthood, mirror imaging 
hGH (Milani et al 2004). IGF-I levels reﬂ  ect the secretory 
activity of growth hormone and are one of a potential num-
ber of markers for identiﬁ  cation of hGH-deﬁ  ciency (GHD), 
hGH-excess (acromegaly), or rhGH administration in sport 
(Powrie et al 2007).
In conjunction with hGH, IGF-I has varying differential 
effects on protein, glucose, lipid, and calcium metabolism and 
therefore body composition (Mauras and Haymond 2005).
Growth hormone, anxiety, 
and depression
Much of our knowledge of the psychological effects of 
hGH has been learned from the GHD model. Using the Not-
tingham Health Proﬁ  le (NHP) and the Psychological Well-
being Schedule (PGWS), hGH replacement for 6 months 
in deﬁ  cient adults has been shown to improve mental state 
and quality of life (QoL), such as mood and energy levels, 
(McGauley 1989). GHD adults have been noted to have a 
disturbed sleep pattern, which returns to normal on rhGH 
replacement (Aström et al 1990). Decreased psychologi-
cal well-being has been reported in hypopituitary patients 
despite pituitary replacement with all hormones but growth 
hormone (Stabler et al 1992). HGH replacement in GHD has 
been shown to improve emotional control and well-being, 
accompanied by lower scores on anxiety, in adult males with 
altered body image (underestimated body size), low self-
esteem and depression (Riva and Molinari 1995). Interest-
ingly, the hGH response to physiological stimuli is reduced in 
healthy young males with higher psychometrically measured 
depressiveness (Harro et al 1999) and depressed patients 
have a blunted hGH response to hGH releasing hormone 
(Dahl et al 2000). Consequently there has been an increasing 
attraction in hormone replacement therapy to improve health 
and QoL of the healthy elderly, with age-related decline in 
hormone levels, the somatopause (Savine and Sonksen 2000). 
A new 21-item age-related hormonal decline (A-RHDQoL) 
questionnaire is an individualized questionnaire measuring 
perceived impact of age-related hormonal decline in the 
QoL of older males. The internal consistency reliability and 
content validity of the A-RHDQoL are established, but the 
measure is at an early stage of its development and its sen-
sitivity to change and other psychometric properties needs 
to be evaluated in clinical trials of hormone replacement in 
older males (McMillan et al 2003). Discontinuation of rhGH 
treatment of young adults with GHD and then recommencing 
treatment, demonstrated that intra-subject IGF-I levels were 
negatively correlated with depression, fatigue, tension, and 
anxiety and positively with vigor and memory (Stouthart 
Figure 2 The growth hormone somatropin, in its correct 22-kD-hGH form. Three-dimensional structure, generated from the protein data base SWISS PROT. Structural data 
supplied with the help of the program RasMol. The n-terminal amino acid (at the bottom left hand corner) is marked yellow, as are the disulphide bridges (and the sequence 
range missing on the 20 kDa hGH variant). The ranges with an α-Helix-structure are marked in red.Therapeutics and Clinical Risk Management 2008:4(3) 590
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et al 2003). A large proportion of GHD adults complain of 
low energy levels, emotional lability, and mental fatigue and 
have an impaired QoL, and psychiatric morbidity, which 
improves after one month of growth hormone treatment 
(Mahajan et al 2004). The Hospital Anxiety and Depression 
Scale (HADS) questionnaire is a simple, reliable tool for use 
in medical practice (Zigmond and Snaith 1983) and has been 
used to determine the disturbed emotional state of groups of 
psychosomatic patients (Karakula et al 1996). HADS scores 
screen for psychiatric morbidity (Janson et al 1994), predicts 
psychosocial and physical outcome (Herrmann 1997), and 
have been used extensively with high validity in psychiatric 
outpatients (Martin et al 2003). This information is freely 
available to informed individuals in the recreational ﬁ  tness 
industry and elite sport who wish to improve their physiques 
(Baker et al 2006). Such individuals who abuse AAS, rhGH, 
and insulin, are aware that rhGH increases fat loss and that 
insulin prevents proteolysis, as a consequence they abuse 
both these hormones either alone or in combination, with 
or without AAS.
Effects of hGH on anthropometry, 
strength, and exercise performance
RhGH administration has therapeutic value as a replacement 
therapy for GHD adults, increasing lean body mass (LBM) 
and reducing total and visceral fat (Johannsson et al 1997). 
Aerobic performance (V ˙O2 peak) increased in GHD and 
reversed following cessation (Gullestad et al 1997).
Five years of rhGH replacement therapy in elderly adults 
with GHD normalized knee ﬂ  exor strength, knee extensor 
strength, and handgrip strength (Gotherstrom et al 2005). 
rhGH increases lipid mobilization and oxidation, decreasing 
protein oxidation and increasing protein synthesis (Horber 
and Haymond 1990).
The use of acipimox (an antilipolytic) with rhGH 
administration in a 37-hour fasting state, which eliminated 
the ability of hGH to restrict fasting protein loss, indicated 
that stimulation of lipolysis by hGH is its principle protein-
conserving mechanism (Nørrelund et al 2003). Such effects 
are associated with signiﬁ  cantly increased lean body mass 
and have been translated into signiﬁ  cantly increased aerobic 
performance (Liu et al 2003). Myostatin, a cytokine impli-
cated in differentiated skeletal muscle growth, is a member 
of the transforming growth factor-beta (TGFß) family that 
has gained attention due to its remarkable expression proﬁ  le 
and dramatic actions. Myostatin messenger-ribonuceleic 
acid (mRNA) expression is signiﬁ  cantly inhibited by rhGH. 
Myostatin mRNA expression was signiﬁ  cantly inhibited to 
31% by rhGH, compared with controls and sustained after 
18 months, signiﬁ  cantly increasing V ˙O2 peak, in GHD (Liu 
et al 2003). In humans, hyper-catabolic states such as human 
immunodeﬁ  ciency virus (HIV) associated wasting, have been 
categorised by marked upregulation of myostatin (Gonzalez-
Cadavid et al 1998).
Reproduction of such results has not been forthcoming 
in healthy young adults, but has been identiﬁ  ed in an infant 
with a mutation of the myostatin gene and was associated 
with gross muscle hypertrophy (Schuelke et al 2004).
Effects in apparently healthy individuals
The ﬁ  rst researchers experimented on athletes using bio-
synthetic methionyl hGH (met-hGH), consisting of 192 
amino-acids, as opposed to recombinant hGH, consisting of 
191 amino acids (Crist et al 1988).
Met-hGH (2.67 mg [~8 IU] 3 days per week) for 6 weeks 
in 8 well-trained exercising adults (22–33 years of age) who 
trained with progressive resistance exercise significantly 
decreased body fat and signiﬁ  cantly increased LBM. Five sub-
jects had a suppressed hGH response to stimulation from either 
L-dopa, arginine or sub-maximal exercise (Crist et al 1988).
One might postulate that rhGH administration would 
beneﬁ  t elderly males, decreasing adiposity and increasing 
LBM (principally muscle). Rudman and colleagues (1990, 
1991) demonstrated such evidence. However, they did not 
demonstrate increased strength.
Acute administration of either rhGH, or IGF-I, in normal 
healthy humans in the post-absorptive state, signiﬁ  cantly 
increased forearm net balance of amino acids (Fryburg 
et al 1991). The effects are claimed to occur through the 
stimulation of protein synthesis rather than decreased protein 
breakdown.
However, increased LBM does not appear to have 
been translated into increased strength or power in young 
healthy individuals who have never previously used per-
formance-enhancing drugs. For example, administration 
of rhGH appears to cause no further increase in muscle 
mass or strength than provided by resistance training in any 
healthy young athletes with a mean age of 23 years (Crist 
et al 1988; Yarasheki et al 1992, 1993; Deyssig 1993) or 
indeed in healthy elderly males with a mean age of 67 years 
(Taaffe et al 1994; Yarasheki et al 1995). There has been no 
substantial evidence that it can increase strength in healthy 
males and females greater than sixty years of age (Zachwieja 
and Yarasheki 1999).
The rate of protein synthesis, identiﬁ  ed as the rate of 
incorporation of amino acids labelled with stable isotopes into Therapeutics and Clinical Risk Management 2008:4(3) 591
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muscle, is required to determine the response of muscle, over 
short periods of time, such as hours or days (Rennie 2003). 
This technique was not available to early researchers and is 
still not freely available.
RhGH administration did not enhance the muscle anabo-
lism associated with heavy-resistance exercise in 16 males 
with a mean age of 27 years and a weight of 70.6 kg.
Resistance training, plus rhGH group (0.04 mg.kg−1.day−1 
[~8.4 IU.day−1]) did not differ from 9 resistance train-
ing males, compared with 9 placebo males for 12 weeks 
(Yarasheki et al 1992).
The fractional rate of skeletal muscle protein synthesis 
and the whole body rate of protein breakdown did not 
increase during a constant intravenous infusion of [13C] 
leucine in 7 young healthy experienced male weightlift-
ers with a mean age of 23 years and a mean weight of 
86.2 kg before and at the end of 14 days of subcutaneous 
rhGH administration (0.04 mg.kg−1.day−1 [~10.5 IU.day−1]) 
(Yarasheki et al 1993).
RhGH administration in 8–10 healthy, nonobese males 
with a mean age of 23 years, body weight of 122 kg, and 
body fat of 10.1% (0.03 mg.kg−1.day−1 [~11 IU.day−1]) for a 
period of 6 weeks, had no effect on maximal strength during 
concentric contraction of the biceps and quadriceps muscles 
(Deyssig et al 1993). In such highly trained athletes with such 
a low fat mass there were no effects of rhGH treatment on 
strength or body composition.
The administration of rhGH to 8 healthy, sedentary males 
(0.0125–0.024 mg.kg−1.day−1; [2.9–5.6 IU.day−1]) versus 
placebo administration to15 healthy, sedentary males, with 
low serum IGF-I levels, with a mean age of 67 years and a 
body mass of 78.5 kg, for 16-weeks, did not increase muscle 
strength over resistance exercise training (Yarasheki et al 
1995). These results may be as a consequence of the differ-
ent dosages of rhGH used, because of adverse side effects 
incurred dosages ranged from 0.013–0.024 mg.kg−1.day−1 
(0.04–0.072 IU.kg−1.day−1). The dosages for the ﬁ  rst two 
subjects were equivalent to 5 IU.day−1 but the second two 
subjects had 4 IU.day−1 and the last four subjects had the 
equivalent of 3 IU.day−1.
RhGH administration (0.03 mg.kg−1of body weight [7.2 
IU × 3.week−1]), for 6 months in 52 healthy males with a mean 
age of 75 years and a body mass of 80 kg, with well-preserved 
functional ability, but low baseline IGF-I levels, signiﬁ  cantly 
increased LBM, by 4.3%. There were no statistically or 
clinically signiﬁ  cant differences seen between the groups 
in knee or hand grip strength, nor in aerobic performance 
(Papadakis et al 1996).
Wallace and colleagues (1999) demonstrated that there 
was no improvement in morphological or performance 
characteristics, assessed by cycle ergometry and V ˙O2 peak 
assessment, following rhGH administration to 8 males 
(0.05 mg.kg−1.day−1 [0.15 IU.kg−1.day−1]) versus placebo 
administration to 8 males, for 7 days.
The combined effects of testosterone and rhGH, 
administration for 1 month, signiﬁ  cantly improved aerobic 
performance in “stair climb time” in 10 healthy older males 
(Brill et al 2002).
A single rhGH dose (2.5 mg [7.5 IU]) in 7 highly trained 
males with a mean age of 26 years, body mass of 77 kg, and 
a V  ˙O2 peak of 65 ml.min−1.kg−1, who performed 90 min of 
cycling 4 hours after taking the rhGH, prevented two sub-
jects from completing the exercise protocol. It signiﬁ  cantly 
increased plasma lactate and glycerol as well as serum NEFA. 
This may compromise exercise performance. V ˙O2 peak 
remained unaltered by drug effect until exhaustion (Lange 
et al 2002a). Plasma glucose was, on average, 9% higher 
during exercise after rhGH administration compared with 
placebo. Any beneﬁ  t of exercise in terms of increased glucose 
tolerance appeared to be negated by rhGH in the subjects.
Myosin heavy chain (MHC) 2X isoforms, were signiﬁ  -
cantly increased by rhGH administration in healthy elderly 
males (Lange et al 2002b). This has been regarded as a 
change into a more youthful MHC composition, possibly 
induced by the rejuvenation of systemic IGF-I levels. There 
was no effect on isokinetic quadriceps muscle strength, 
power, cross-sectional area (CSA), or ﬁ  bre size. Resistance 
training (RT) and placebo caused substantial increases in 
quadriceps isokinetic strength, power, and CSA; but these 
RT-induced improvements were not further augmented by 
additional rhGH administration. In the RT and rhGH group, 
there was a signiﬁ  cant decrease in MHC 1 and 2X isoforms, 
whereas MHC 2A increased.
Resistance training, therefore, seems to overrule the changes 
in MHC composition induced by rhGH administration alone.
Blackman and colleagues (2002) administered rhGH 
(0.03–0.02 mg.kg−1.day−1) and gender related sex steroids to 
healthy aged males and females, aged 65–88, for 26 weeks. 
LBM increased and fat mass decreased. Testosterone and 
rhGH increased V ˙O2 peak in males, but transdermal oes-
tradiol, 100 µg.d−1, plus oral medroxyprogesterone acetate, 
10 mg.d−1 and rhGH did not increase female V ˙O2 peak. The 
effect on strength and endurance exercise could not entirely 
be attributed to the administration of rhGH.
The administration of rhGH in a dosage of 0.067 mg.kg −1.
day−1 (~15.3 IU.day−1) exerts an anabolic effect both at rest Therapeutics and Clinical Risk Management 2008:4(3) 592
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and during exercise in 6 endurance-trained athletes versus 
5 controls, with a mean age of 31 years, measuring whole 
body leucine turnover. Plasma levels of glycerol and free 
fatty acids and glycerol rate of appearance (Ra) at rest, during 
and post exercise increased during rhGH treatment compared 
with placebo. Glucose Ra and glucose rate of disappearance 
(Rd) were greater during rhGH treatment compared with 
placebo (Healy et al 2003).
Resting energy expenditure and fat oxidation were 
greater under resting conditions during rhGH treatment 
compared with placebo, in 9 males with a mean age of 24 
years, a weight of 77.3 kg, body fat of 17.7%, and a V ˙O2 peak 
37.9 ml.kg−1.min−1, who completed 6 × 30-minute randomly 
assigned cycle ergometry exercise trials. An rhGH infusion 
(0.01 mg.kg−1, [~2.3 IU]) was followed by a 30-minute 
exercise trial. There were no signiﬁ  cant condition effects for 
total work, caloric expenditure, heart-rate response, the blood 
lactate response, or ratings of perceived exertion response 
(RPE). However, acute rhGH administration resulted in 
lower V ˙O2 peak without a drop-off in power output (Irving 
et al 2004). The reduced V ˙O2 peak may be explained by the 
rhGH administration improving exercise economy. This may 
have been as a consequence of production of free fatty acids 
(FFA) by rhGH’s lipolytic effect, providing the substrates 
for the maintenance of energy metabolism, despite the lower 
V ˙O2 peak.
There was no increase observed in the strength in 30 
physically active and healthy individuals of both genders 
with a mean age 25.9 years. Ten subjects each received 
rhGH (0.033 mg.kg−1.day−1) or rhGH (0.067 mg.kg−1.day−1) 
or placebo for 1 month. IGF-I signiﬁ  cantly increased by 
134%, and there were signiﬁ  cant increases observed for body 
weight (2.7%), LBM (5.3%), total body water (6.5%), and 
extracellular water (ECW) (9.6%). Body fat signiﬁ  cantly 
decreased by 6.6% (Ehrnborg et al 2005).
There was no increase in power or V ˙O2 peak in 30 
physically active and healthy individuals of both gen-
ders, with a mean age of 26 years who received rhGH 
(0.033 mg.kg−1.day−1) or rhGH (0.067 mg.kg−1.day−1) or 
placebo for 1 month (Berggren et al 2005).
Plasma levels of glycerol and free fatty acids increased 
at rest and during exercise during rhGH administration 
(0.067 mg.kg−1.day−1) for 4 weeks, in 6 trained male athletes 
compared with controls. This had the effect of increasing resting 
energy expenditure and fat oxidation and increasing glucose 
production and uptake after exercise (Healy et al 2006).
Six days of rhGH administration (0.019 mg.kg−1.day−1
[~5 IU.day−1]) by 24 abstinent male AAS-users, with a 
mean age of 32 years compared with controls, increased 
forced expiratory volume in one second/forced vital capac-
ity (FEV1/FVC), maximum inspiratory pressure, maximum 
expiratory pressure, and V ˙O2 peak (Graham et al 2007b). It 
is possible that previous use of AAS, had increased the num-
ber of myonuclei per muscle ﬁ  ber, to such an extent that a
12-week washout program was an insufﬁ  cient time interval 
for return of the proportion of central nuclei to baseline 
(Eriksson et al 2005).
Athletes continue to abuse both cadaver pituitary hGH 
and rhGH in the belief that such effects can be extrapolated 
to the healthy individual (Crist et al 1988; Deyssig et al 
1993). The abuse of cadaver pituitary hGH has diminished in 
Europe, subsequent to its association with Jacob-Creutzfeldt 
disease and the abundant Internet availability of rhGH from 
China. The acclaim of the anabolic properties of growth 
hormone appeared in the underground doping literature 
as early as 1983 (Duchaine 1983). Its abuse has increased 
(Baker et al 2006) despite early research demonstrating its 
effect on functional abilities, is no greater than exercise alone 
in healthy young males (Yarasheki et al 1992) or elderly 
males (Yarasheki et al 1995) and the demonstration that 
supraphysiological dosages can have fatal consequences 
(Takala et al 1999).
Both hGH and rhGH are believed to stimulate production 
of class-1 isoforms of IGF-I locally in muscles and tendons. 
These may have a preventative effect on rupture of muscles 
and tendons in AAS-induced hypertrophy (Doessing and 
Kjaer 2005). The transmission of force from muscle ﬁ  bres 
to bone, could be explained by the stimulating effect of hGH 
on collagen synthesis. Such strengthened connective tissue 
would provide a more strain-resistant musculo-tendinous 
junction and could explain why there is still a claimed effect 
of rhGH on athletic performance. Previous studies in humans 
have not shown an increase in endurance exercise or strength 
in drug naive young athletes, solitarily due to rhGH, but it has 
been suggested that such differences were not signiﬁ  cant due 
to a lack of power, given the relatively small sample sizes. 
The relevance of these effects for athletic performance would 
suggest enhancement under circumstances where an athlete 
cycles AAS and then administers rhGH in the abstinent phase 
in an attempt to circumvent a doping violation.
Physiology and biochemistry 
of Insulin
Insulin is a 2 chain (30 and 21 amino-acids) polypeptide hor-
mone (51 amino-acids, 5808 molecular weight) synthesized 
and secreted by the beta-cells of the islets of Langerhans in Therapeutics and Clinical Risk Management 2008:4(3) 593
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the pancreas gland. The entry of a water-soluble substrate 
such as glucose across an impermeable lipid bi-layer into 
a cell requires a speciﬁ  c transport mechanism. These protein 
carriers are known as glucose ‘transporters’ (GLUTs). In the 
case of glucose there are at least six types and they tend to be 
tissue-speciﬁ  c. In the case of muscle the transporter is called 
‘Glut 4’. It is normally present in excess in the cell membrane 
even in the absence of insulin and is not rate limiting for 
glucose entry into the cell (Sonksen 2001). Insulin acts in 
a stimulatory and an inhibitory manner (Schafer 1916). It 
stimulates the translocation of ‘Glut 4’ from the cytoplasm 
of muscle and adipose tissue to the cell membrane. This 
increases the rate of glucose uptake to values greater than in 
the basal state without insulin, shown in isolated adipocytes 
from rats (Figure 3) (Thomas et al 1979).
There are a sufﬁ  cient number of glucose transporters in 
all cell membranes at all times to ensure enough glucose 
uptake, to satisfy the cell’s respiration, even in the absence of 
insulin. Insulin increases the number of these transporters in 
some cells but glucose uptake is never truly insulin-dependent 
(Sonksen, 2001).
In Figure 3, it can be seen that simultaneously with 
insulin’s excitatory action in stimulating lipogenesis, insu-
lin also exhibits an inhibitory action in preventing glycerol 
release. It is this inhibitory action on lipolysis (and also 
glycolysis, gluconeogenesis, ketogenesis, and proteolysis) 
that accounts for most of insulin’s physiological actions in 
man. The inhibitory actions are also responsible for insulin’s 
net anabolic actions.
Insulin increases glucose metabolism more through 
reducing FFA and ketone levels than it does through recruit-
ing more GLUTs into the muscle cell membrane. Insulin 
does, however, have a direct action recruiting more GLUTs 
into muscle cell membranes. This facilitates glucose uptake 
which is reﬂ  ected as an increase in the metabolic clear-
ance rate (MCR) of glucose, measured with isotope tracer 
technology and is a nonlinear function of blood glucose 
concentration, increasing as glucose concentration falls and 
insulin levels rise (Sonksen and Sonksen 2000). Glucose 
transport into the cell is mainly determined by the con-
centration gradient between the extracellular ﬂ  uid and the 
intracellular ‘free’ glucose. ‘Free’ glucose is very low inside 
the cell as it is immediately phosphorylated. In uncontrolled 
diabetes, particularly where there is a high concentration of 
FFA and ketones, glycolysis is inhibited, phosphorylation 
of ‘free’ glucose stops and intracellular ‘free’ glucose rises. 
Insulin recruits more transporters into the cell membrane 
from an intracellular pool. This increases the rate of glucose 
entry for a given glucose concentration and this is reﬂ  ected 
in vivo by an increase in the MCR of glucose, which is an 
in vivo measure of substrate transporter activity (Boroujerdi 
et al 1995).
Experiments in normal subjects using hyperglycaemic 
and hyperinsulinaemic ‘clamps’ have shown the importance 
Figure 3 Insulin exhibits both inhibitory and excitatory actions via the same receptor. In these experiments carried out on rat adipose tissue, in vitro insulin simultaneously 
inhibits lipolysis (the release of glycerol from stored triglyceride) and stimulates lipogenesis (formation of stored triglyceride from glucose). Thus its anabolic action is due 
to two mechanisms working synergistically. Copyright © 1979 Royal Society of Medicine. Reproduced with permission from Thomas SHL, Wisher MH, Brandenburg D, et al. 
1979. Insulin action on adipocytes. Evidence that the anti-lipolytic and lipogenic effects of insulin are medicated by the same receptor. Biochem J, 184:355–60.Therapeutics and Clinical Risk Management 2008:4(3) 594
Graham et al
of both glucose and insulin concentrations in determining 
glucose uptake (Gottesman et al 1982).
Insulin, anxiety, and depression
There is a correlation between substance misuse and 
inappropriate compliance with treatment in chronic medical 
conditions, which can induce anxiety and depressive 
disorders (Weiss et al 1998). Insulin dependent diabetics 
(type 1) have higher co-morbid substance misuse compared 
with the general population (Kovacs et al 1997) and their 
compliance with their medical management is reduced 
(Morris et al 1997). Insulin dependent diabetics have an 
increased incidence of a psychiatric disorder, predominantly 
in the early course of their condition (Kovacs et al 1997). 
Treating the psychiatric disorder improves diabetic control 
(Lustman et al 1997).
Hypoglycemia is a regular occurrence in insulin-
dependent diabetics (Potter et al 1982) and may be associated 
with cognitive and affective outcomes (Gonder-Freerick et al 
1997). Mood changes induced by ﬂ  uctuations in glycemic 
control are characteristically individual, with depressive 
and anxiety affective states being most prevalent, however 
euphoria can also occur (Gonder-Freerick et al 1989). The 
literature is interspersed with cases of deliberate misuse of 
insulin, associated with either suicide, parasuicide or facti-
tious illness (Kaminer and Robbins 1989; Cassidy et al 1997). 
Even intelligent individuals have abused their therapeutically 
prescribed insulin to induce feelings of “happiness, disori-
entation, drunkenness, altered perception of helplessness, 
and euphoria” (Cassidy et al 1997). However, there always 
appears to be an underlying mood or personality disorder 
(Scaramuzza et al 1996).
There appears to be a class of individuals who are not 
diabetic and inject insulin to induce euphoria, to alter 
perception and for the “exquisite pleasure” associated 
with the risk of death (Odie 1968; Retsas 1972; Scarlett 
et al 1977).
A cohort of patients referred to a deliberate self-harm 
team was asked to complete the HADS questionnaire. The 
HADS gave a sensitivity of 88% and a positive predictive 
value of 80% (Hamer 1991). Eighty percent of 56 hypogly-
cemic patients admitted to an urban teaching hospital in a 
12 month period were diabetics receiving insulin. Twenty 
percent were as a consequence of deliberate self-poisoning 
with insulin and had a history of psychiatric disorder (Hart 
and Frier 1998). A bodybuilder, who took 70 IU insulin for 
its anabolic effect, suffered hypoglycemic convulsions due 
to neuroglycopaenic coma (Konrad et al 1998).
Insulin effects on anthropometry, 
strength, and exercise performance
Glucose metabolism significantly increased following 
exogenous insulin in trained athletes. V   ˙O2 peak also signiﬁ  -
cantly increased (Sato et al 1986).
Insulin’s anabolic actions are believed to improve per-
formance, by increasing protein synthesis (Bonadonna et al 
1993; Kimball et al 1994) and inhibiting protein catabolism 
and enhancing transport of selected amino acids in human 
skeletal muscle (Biolo et al 1995). Physiological hyperin-
sulinemia stimulates the activity of amino acid transport in 
human skeletal muscle, thereby stimulating protein synthesis 
(Bonadonna et al 1993).
Insulin-treated diabetics are known to have increased 
lean body mass versus controls (Sinha et al 1996). In addi-
tion to its role in regulating glucose metabolism, insulin 
increases amino acid transport into cells. Its stimulation of 
lipogenesis, and diminished lipolysis, is one of the reasons 
why bodybuilders and athletes will take rhGH in conjunction, 
to counteract this adverse effect, whilst optimizing protein 
synthesis (Sonksen 2001).
It is the inhibition of proteolysis that the athlete is inter-
ested in and the physiology of the diabetic patient has been 
extrapolated by the athlete to the sporting arena. Insulin 
administration is protein anabolic in the insulin-resistant 
state of chronic renal failure. It inhibits proteolysis and 
when administered with amino-acids, it increases net protein 
synthesis (Lim et al 2003).
The administration of exogenous insulin, establishes an 
in-vivo hyperinsulinemic clamp, increasing muscle glyco-
gen before and in the recovery stages of strenuous exercise. 
This may increase power, strength, and stamina and assist 
in recovery from strenuous exercise.
Secondly, by inhibiting muscle protein breakdown and 
in conjunction with a high protein and high carbohydrate 
diet, insulin will have the action of increasing muscle bulk, 
potentially improving performance.
Conclusion
Strength and performance increase by the administration 
of rhGH and insulin in healthy young adults would appear 
possible by pharmacological manipulation, however cur-
rent review of the literature suggests otherwise, in young, 
healthy, drug-naive individuals . Psychological improvement 
in abstinent AAS abusers by rhGH has been demonstrated 
(Graham et al 2007a), but no published research has been 
conducted in interventive insulin abuse in sport. Further 
research into the continued abuse of these drugs may assist Therapeutics and Clinical Risk Management 2008:4(3) 595
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in our understanding of the psychological and social reasons 
why individuals take these drugs, when current information 
appears unconvincing.
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